Technology
Health
Biotechnology
NovaBay Pharmaceuticals
$1.379876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$1.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.02 (1.48%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell NBY and other stocks, options, ETFs, and crypto commission-free!
About
NovaBay Pharmaceuticals, Inc., also called NovaBay Pharmaceuticals, is a biopharmaceutical company, which engages in commercializing and developing products for eye care. Its products include Avenova, NeutroPhase, and CelleRx. Read More The comapny was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.
Employees
86
Headquarters
Emeryville, California
Founded
2000
Market Cap
23.07M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
16.26K
High Today
$1.38
Low Today
$1.35
Open Price
$1.36
Volume
8.29K
52 Week High
$3.85
52 Week Low
$0.71
Collections
Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
US
North America
News
Seeking AlphaMar 13
NovaBay downsizes on strategy change
Citing a "strategic shift" in its commercialization approach, NovaBay Pharmaceuticals (NYSEMKT:NBY) will now sharpen its focus on selling Avenova in areas that have the most volume potential.
Yahoo FinanceMar 12
NovaBay Pharmaceuticals Announces Strategic Shift in U.S. Avenova Commercialization Strategy
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Makes board and executive changes and reduces U.S. sales organization to focus only on high-performing, high potential sales territories and specialty pharmacy channel expansion Company to hold 2018 fourth quarter and full year conference call on March 28, 2019 NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces a strategic shift in its U.S. comm...
Yahoo FinanceMar 12
Analysts Estimate NovaBay Pharmaceuticals (NBY) to Report a Decline in Earnings: What to Look Out for
The market expects NovaBay Pharmaceuticals (NBY) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
Price Paid on Robinhood
51% Lower
Right Now
52 Week Low
$0.71
Average Price Paid
$2.78
52 Week High
$3.85
Earnings
-$0.16
-$0.10
-$0.04
$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.08 per share
Actual
Available Mar 28, After Hours